Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...
Medscape9d
FDA Okays Subcutaneous Ocrelizumab for MS
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
emjreviews.com6d
Roche’s twice-yearly MS injection wins FDA approval
The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple ...
The Pharma Letter3d
Strong new data for Briumvi in MS
TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...
Pharmabiz2d
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
reinsurancene4d
US private market insured losses from Francine to be under $2bn: Moody’s RMS
Moody’s RMS Event Response has disclosed an estimate for US private market insured losses from Hurricane Francine, which made ...
The American Journal of Managed Care5d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
BioSpace16d
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...
The Pharma Letter6d
Roche scores first, with FDA approval of Ocrevus Zunovo for MS
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment ...
Hosted on MSN6d
Leerink Partners Likes “Risk/Reward” of Immunic’s CALLIPER Readout
Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...
Business Insider20d
Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS
Addressing disability accumulation, thought to be driven by smoldering neuroinflammation, remains the greatest unmet medical need in people with non-relapsing secondary progressive MS today." ...